Identify microRNAs in Cachexia in Pancreatic Carcinoma

NCT05275075 | Recruiting

• 1 other identifier: OU-SCC-MIRPANCA
• Study Type: observational
• Target: 100
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to determine the proportion of pancreatic patients who experience weight loss and cachexia, and to identify any differences in the genes between patient groups.

Conditions

Resectable Pancreatic Adenocarcinoma

Keywords

pancreatic cancer; cachexia; microRNA; mRNA; PDAC

Outcome Measures

Primary Outcomes (1)

• Proportion of African American pancreatic cancer patients with weight loss and cachexia.

  Evaluate weight loss and the markers of cachexia, albumin and psoas cross-sectional area, to see if African Americans with pancreatic cancer patients experience Grade I-IV cachexia at a higher frequency than other racial groups.

  1 - 12 months

Secondary Outcomes (2)

• Differences in microRNA and messenger RNA tumor expression profiles in all cancer patients undergoing pancreatic surgery.

  1 - 12 months

• Differences in cachexia-associated RNA signatures in African American pancreatic cancer patients, and other racial groups.

  1 - 12 months

Study Arms (1)

Pancreatic Cancer Cohort

All eligible adenocarcinoma pancreatic cancer patients with operable cancer.

Other: Pancreatic cancer microRNA and messenger RNA expression.

Interventions

Pancreatic cancer microRNA and messenger RNA expression. OTHER

Tumor specimens from pancreatic patients will be analyzed for markers associated with muscle loss.

Pancreatic Cancer Cohort

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

The study population is inclusive of all races, ethnicities, and gender. Enrollment into the study is restricted to Stephenson Cancer Center site, part of the University Oklahoma Health Sciences Center.

You may qualify if:

• Male or female patient, who is ≥ 18 years old at the time of informed consent.
• Patients with operable pancreatic tumors diagnosed in the last 12 months prior to consent with clinical discretion or pathology confirmed as adenocarcinoma.
• Patient has stage I or higher disease who is considered a candidate for surgical resection of pancreatic cancer, with or without neoadjuvant chemotherapy.
• Ability to provide written informed consent and HIPAA authorization.

You may not qualify if:

• Patients with pancreatic adenocarcinoma who do not meet the criteria for surgical resection.
• Patient has cancer diagnosis other than primary pancreatic adenocarcinoma.

Sponsors & Collaborators

• University of Oklahoma: lead

Study Sites (1)

Stephenson Cancer Center

Oklahoma City, Oklahoma, 73117, United States

RECRUITING

Biospecimen

Retention: SAMPLES WITH DNA

After surgical removal of the pancreatic cancer, part of the tumor tissue will be collected to analyze genes and RNA related to muscle loss in patients with pancreatic tumors. A portion of the tumor will be archived in a repository for future use related to this study.

MeSH Terms

Conditions

Pancreatic Neoplasms; Cachexia

Condition Hierarchy (Ancestors)

Digestive System Neoplasms; Neoplasms by Site; Neoplasms; Endocrine Gland Neoplasms; Digestive System Diseases; Pancreatic Diseases; Endocrine System Diseases; Weight Loss; Body Weight Changes; Body Weight; Signs and Symptoms; Pathological Conditions, Signs and Symptoms; Thinness

Study Officials

• Ajay Jain, MD

  University of Oklahoma Stephenson Cancer Center

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Lead Nurse

CONTACT

405.271.8777; scc-iit-office@ouhsc.edu

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 2, 2022
• First Posted: March 11, 2022
• Study Start: December 7, 2022
• Primary Completion: May 1, 2026
• Study Completion (Estimated): May 1, 2029
• Last Updated: January 8, 2026

Record last verified: 2026-01

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)